Cost and practical considerations Beyond the science, practical factors influence whether this combination makes sense for individual researchers
The authors themselves described it as a small preliminary study.[15] A 2025 pilot report described intravenous administration to two healthy adults at doses up to 20 mg, with no measurable changes in cardiac, hepatic, renal or thyroid biomarkers and no reported adverse effects.[16] Two individuals cannot characterise uncommon reactions, immunogenicity, long-term toxicity, reproductive safety or oncological risk
Claudia Fox, MD, MPH , co-director of the Center for Pediatric Obesity Medicine at University of Minnesota Medical School, said the level of BMI reduction in the semaglutide group was close to that seen with bariatric surgery
If you're designing a tesofensine protocol, map every compound's mechanism before you dose